Characterization of Fabry mice treated with recombinant adeno-associated virus 2/8-mediated gene transfer
<p>Abstract</p> <p>Background</p> <p>Enzyme replacement therapy (ERT) with α-galactosidase A (α-Gal A) is currently the most effective therapeutic strategy for patients with Fabry disease, a lysosomal storage disease. However, ERT has limitations of a short half-life, r...
Main Authors: | Choi Jin-Ok, Lee Mi, Park Hae-Young, Jung Sung-Chul |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2010-04-01
|
Series: | Journal of Biomedical Science |
Online Access: | http://www.jbiomedsci.com/content/17/1/26 |
Similar Items
-
Recombinant adeno-associated virus 8 vector in gene therapy: Opportunities and challenges
by: Liyuan Zhao, et al.
Published: (2024-01-01) -
Donor template delivery by recombinant adeno-associated virus for the production of knock-in mice
by: Graham Duddy, et al.
Published: (2024-02-01) -
Advances in Recombinant Adeno-Associated Virus Vectors for Neurodegenerative Diseases
by: Leyao Li, et al.
Published: (2023-10-01) -
Systemic delivery of MicroRNA using recombinant adeno-associated virus serotype 9 to treat neuromuscular diseases in rodents
by: Pourshafie, N, et al.
Published: (2018) -
Comparison of different technologies for producing recombinant adeno-associated virus on a laboratory scale
by: E. I. Ryabova, et al.
Published: (2021-12-01)